Artivion, Inc. Hits New 52-Week High of $46.58, Up 96.65%

Artivion, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 46.58 on November 4, 2025. This achievement underscores the company's remarkable performance over the past year, with a striking increase of 96.65%, significantly outpacing the S&P 500's growth of 19.89% during the same period.
With a market capitalization of USD 2,114 million, Artivion operates in a competitive industry where innovation and market positioning are crucial. The company's financial metrics reveal a debt-to-equity ratio of 0.40, indicating a manageable level of debt relative to its equity. However, it is important to note that Artivion is currently loss-making, as reflected by its negative return on equity of -1.88%. The stock does not offer a dividend yield, which is common among growth-focused biotech firms.

The achievement of this new high price reflects the underlying trends and developments within the company and the broader market dynamics in the pharmaceuticals and biotechnology industry.